Form 4: Atea Pharmaceuticals Director Polly A. Murphy Reports Acquisition of Stock Options and Restricted Stock Units

Director Polly A. Murphy reported the acquisition of stock options and restricted stock units in Atea Pharmaceuticals on June 21, 2024.

Summary

• On June 21, 2024, Polly A. Murphy, a director of Atea Pharmaceuticals, reported acquiring 41,200 stock options with an exercise price of $3.44, expiring on June 20, 2034.
• These options vest in twelve equal monthly installments from the grant date.
• Murphy also acquired 29,600 restricted stock units, which convert to common stock on a one-for-one basis.
• These RSUs vest on the earlier of the next annual meeting or the first anniversary of the grant date, contingent on continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock options and restricted stock units granted to a director. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard compensation practices.

Positives

• The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by a director may have a minor positive impact on shareholder sentiment.

Key Dates